Business Wire

EverZinc Invests in Zano®

4.12.2018 16:30:00 EET | Business Wire | Press release

Share

EverZinc, the leading global provider of specialty zinc materials, today announced an investment of more than 5 Million Euros in order to increase the production capacity of the Zano® (ultra-fine zinc oxide) product line. Production capacity of EverZinc has been increased by 30% in 2018 and will increase further by another 30% in 2019. EverZinc is also investing in an additional Zano® production line, which is scheduled to be operational from Q1 2020 onwards. This new line will expand EverZinc’s current Zano capacity by another 50%. In total EverZinc is going to triple the production capacity of Zano® in this 48-month period.

The market for UV filters is envisaging major changes, and there is a growing demand for ultra-fine zinc oxide as a mineral UV filter (due to a higher public awareness for UV-A protection, an increasing worldwide interest for natural UV filters, the ban on the chemical filters oxybenzone and octinoxate in several island regions, and the ECHA official opinion about ultra-fine TiO2). “This worldwide trend which is accelerating quickly has resulted in an unforeseen expansion of the zinc oxide suncare market,” said Vincent Dujardin, EverZinc’s Chief Executive Officer. “EverZinc is dedicated to invest in new production capacity of Zano® to support the growth of the zinc-oxide-based sunscreen and skincare market because we believe in the superior characteristics of Zano®, combining broadband UVA/UVB protection and a high level of transparency. Besides, it offers a natural solution to replace chemical filters.”

Following this Capex expenditure, EverZinc is also raising Zano®’s price for material delivered from 1 January 2019 onwards. “Zano®’s price has been stable for many years despite severe cost increases related to energy inflation, zinc’s higher price, carbon emission rights, and staff costs,” concluded Dujardin.

About EverZinc

EverZinc, an OpenGate Capital portfolio company, is committed to creating products that matter. The company is a global provider of specialty zinc materials, including fine zinc powders; zinc oxides; battery zinc powders; and Zano®, an ultra-fine zinc oxide. EverZinc products are used in a wide variety of applications, including corrosion inhibiting paints, performance tires, pharmaceuticals, ceramics, glass, sunscreen, alkaline batteries, and other products. With manufacturing operations located in Belgium, the Netherlands, Norway, China, and Malaysia, EverZinc processes more than 180,000 tons of materials of which 40% are recycled and refined at eight production sites to serve its growing global customer base. Learn more at www.everzinc.com.

To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.

Contact information

Media contact
Grégory Sacré
gregory.sacre@everzinc.com

About Business Wire

For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.

Subscribe to releases from Business Wire

Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.

Latest releases from Business Wire

BeOne Medicines, BeOne Care Foundation, and The Max Foundation Renew Partnership to Expand Access to BRUKINSA® for the Treatment of Chronic Lymphocytic Leukemia in Low- and Middle-Income Countries18.8.2026 13:00:00 EEST | Press release

BeOne Medicines Ltd. (“BeOne”) (Nasdaq: ONC; HKEX: 06160; SSE: 688235), a global oncology company, together with the BeOne Care Foundation, a nonprofit charitable foundation, and The Max Foundation, a leading global health nonprofit organization, today announced the renewal of their partnership through 2028 to expand access to BRUKINSA® (zanubrutinib) for the treatment of chronic lymphocytic leukemia (CLL) in low- and middle-income countries, with the program projected to support approximately 1,000 patients cumulatively. Building on a collaboration launched in 2023, the renewed partnership reflects the organizations’ shared commitment to improving access to innovative cancer treatments in underserved communities. To date, the partnership has enabled access to BRUKINSA for more than 300 patients with CLL across Armenia, Ethiopia, and Nepal, exceeding the program’s original scope by approximately 150 patients and helping establish access to innovative cancer care for patients who previo

Quectel Launches Android 16 Smart Modules for 4G and 5G IoT Devices18.8.2026 11:00:00 EEST | Press release

Quectel Wireless Solutions, a global end-to-end IoT solutions provider, today announces the launch of two new Android 16 smart modules: the SH602FA, a high-performance 4G smart module, and the SE505FE, an entry-level 5G smart module. Designed for industrial and commercial IoT applications, the new modules combine Android 16, integrated wireless connectivity and powerful multimedia capabilities in compact form factors that simplify development and accelerate time-to-market. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260818272981/en/ Quectel launches Android 16 smart modules for 4G and 5G IoT devices By bringing Android 16 to both 4G and 5G IoT devices, Quectel enables developers to build smarter connected products with richer user interfaces, enhanced multimedia performance and seamless integration into modern smart building, retail and industrial environments. Android 16 enables connected devices to communicate more inte

Beno Opens Luxury Waterfront Guest Lounge at Marsa Al Arab in Partnership with Jumeirah Group18.8.2026 10:00:00 EEST | Press release

Beno, Dubai's luxury experiences platform, announced the opening of a new premium guest lounge at Marsa Al Arab, developed in partnership with Jumeirah Group, the hospitality arm of Dubai Holding. The lounge adds a permanently staffed guest-services layer to one of Dubai's newest ultra-luxury marine developments. Marsa Al Arab Marina, operated by D-Marin adjacent to Jumeirah Burj Al Arab, offers 82 berths for yachts of up to 61 metres and holds Superyacht Ready and Blue Flag certifications. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260818185241/en/ Beno's guest lounge on the marina promenade at Marsa Al Arab, Dubai, with the 115-ft yacht Santorini berthed opposite (Photo: AETOSWire) Beno coordinates yacht charters from the lounge, supported by a nine-vessel fleet berthed at the marina. Among them is Santorini, a 115-ft superyacht featuring five cabins that can accommodate up to 12 overnight guests and up to 80 guests fo

Queue-it Announces Majority Investment from THL Partners18.8.2026 10:00:00 EEST | Press release

Queue-it, a global provider of online traffic orchestration solutions, today announced that it has entered a definitive agreement for a majority investment from THL Partners (“THL”), a premier investment firm investing in middle-market growth companies. Together, THL and Queue-it will focus on accelerating product innovation and expanding the company’s global reach. Founded and headquartered in Denmark, Queue-it helps enterprises and public organizations manage online traffic surges, protect digital infrastructure, mitigate bots and abuse, and deliver fair, reliable access to critical online services. Its platform is trusted by organizations around the world and operates across ticketing, retail, government, financial services, and other mission-critical industries. THL’s partnership with Queue-it builds on the firm’s longstanding investment focus on IT Operations & Data, which includes software companies that help organizations operate, secure, and optimize increasingly complex digita

Nanochon Receives Regulatory Approval from Panamá’s Ministry of Health to Initiate First-in-Human Clinical Study of Chondrograft™17.8.2026 22:44:00 EEST | Press release

Nanochon, a medical device company developing Chondrograft™, a novel patented implant for the treatment of articular cartilage defects of the knee, today announced that it has received regulatory approval from Panamá’s Ministry of Health to initiate its First-in-Human (FIH) clinical study in Panamá. The study will evaluate the safety and performance of Chondrograft™ in patients with focal chondral defects of the knee and represents a major milestone in the company’s clinical and regulatory development strategy. The trial will be conducted at The Panama Clinic in Panamá City under the leadership of Drs. Juan Osorio and Emilio Tufiño, experienced sports medicine surgeons, with Dr. Osorio serving as Principal Investigator for the study. Dr. Osorio stated, “I am pleased to be the Principal Investigator for this important study, and we look forward to contributing the data that will support a larger clinical study and subsequent market entry.” Nanochon selected Panamá for its growing reputa

In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.

Visit our pressroom
World GlobeA line styled icon from Orion Icon Library.HiddenA line styled icon from Orion Icon Library.Eye